Payment overview · 2025
General Payments
$327.97
14 reported records · 7 companies
Healthcare provider profile · identity verified
Blake P Melling, MD
Allopathic & Osteopathic Physicians|Family Medicine · MORRISTOWN, TN · NPI 1487605366
Verified facts
What the public records show
CMS Open Payments records show Blake P Melling, MD received $327.97 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 58.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.11 | 58.0% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.74 | 10.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.63 | 6.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.35 | 6.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.59 | 6.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.56 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.99 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.97 | 13 |
| Education | $116.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $179.99 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.99 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 96 |
| Lisinopril | Lisinopril | 254 | 95 |
| Omeprazole | Omeprazole | 249 | 95 |
| Gabapentin | Gabapentin | 206 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 62 |
| Metformin Hcl | Metformin Hcl | 181 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 61 |
| Montelukast Sodium | Montelukast Sodium | 146 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 66 |
| Trazodone Hcl | Trazodone Hcl | 133 | 56 |
| Losartan Potassium | Losartan Potassium | 131 | 44 |
| Meloxicam | Meloxicam | 129 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 44 |
| Sertraline Hcl | Sertraline Hcl | 116 | 40 |
| Alendronate Sodium | Alendronate Sodium | 109 | 34 |
| Furosemide | Furosemide | 109 | 41 |
| Simvastatin | Simvastatin | 106 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 35 |
| Potassium Chloride | Potassium Chloride | 90 | 32 |
| Alprazolam | Alprazolam | 88 | 26 |
| Eliquis | Apixaban | 81 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 23 |
| Atenolol | Atenolol | 76 | 27 |
| Valsartan | Valsartan | 75 | 26 |
| Cefdinir | Cefdinir | 66 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 27 |
| Xarelto | Rivaroxaban | 63 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 15 |
| Metformin Hcl Er | Metformin Hcl | 60 | 23 |
| Prednisone | Prednisone | 60 | 48 |
| Famotidine | Famotidine | 57 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 21 |
| Lorazepam | Lorazepam | 56 | 16 |
| Ezetimibe | Ezetimibe | 55 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 18 |
| Carvedilol | Carvedilol | 53 | 21 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Ozempic | Semaglutide | 52 | 18 |
| Donepezil Hcl | Donepezil Hcl | 50 | 26 |
| Enalapril Maleate | Enalapril Maleate | 50 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 17 |
| Allopurinol | Allopurinol | 48 | 16 |
| Glipizide | Glipizide | 48 | 16 |
| Januvia | Sitagliptin Phosphate | 48 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 26 |
| Buspirone Hcl | Buspirone Hcl | 45 | 15 |
| Spironolactone | Spironolactone | 44 | 16 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Pregabalin | Pregabalin | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 15 |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | 11 |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Temazepam | Temazepam | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 12 |
| Warfarin Sodium | Warfarin Sodium | 29 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Promethazine Hcl | Promethazine Hcl | 28 | 13 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | 11 |
| Celecoxib | Celecoxib | 26 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Wegovy | Semaglutide | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | 12 |
| Jardiance | Empagliflozin | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Clonidine | Clonidine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Colchicine | Colchicine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.97 · 14 records | Novo Nordisk Inc | AREXVY, Auvelity, FARXIGA, GVOKE HYPOPEN, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error